{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:28Z","timestamp":1793664808231,"version":"4.5.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ekir.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T19:13:02Z","timestamp":1738955582000},"page":"1441-1449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series"],"prefix":"10.1016","volume":"10","author":[{"given":"Orhan","family":"Efe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Sauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish S.","family":"Seethapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank B.","family":"Cortazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Zonozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.02.002_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib2","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for Maintenance in ANCA-Associated Vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.02.002_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.02.002_bib4","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1038\/s41598-023-32576-7","article-title":"Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS","volume":"13","author":"Osterholt","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.02.002_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ckj\/sfy067","article-title":"Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome","volume":"12","author":"Cortazar","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.02.002_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2009.141","article-title":"B-cell-directed therapies for autoimmune disease","volume":"5","author":"D\u00f6rner","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ekir.2025.02.002_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-Associated Vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.02.002_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-Associated Renal Vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.02.002_bib9","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.02.002_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: A case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib11","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.02.002_bib12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.02.002_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: A randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ekir.2025.02.002_bib15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.ekir.2025.02.002_bib16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00296-019-04272-1","article-title":"Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases","volume":"39","author":"Vikse","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ekir.2025.02.002_bib17","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2025.02.002_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ndt\/gfad197","article-title":"Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function","volume":"39","author":"Mescia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.02.002_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: A longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2025.02.002_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/acr2.11074","article-title":"Patterns of B cell repletion following rituximab therapy in a pediatric rheumatology cohort","volume":"1","author":"Mitchell","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ekir.2025.02.002_bib21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/ard.2008.091124","article-title":"Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: A report of two cases","volume":"67","author":"Lu","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.02.002_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916934.2014.914174","article-title":"Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease","volume":"47","author":"Venhoff","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.ekir.2025.02.002_bib24","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/art.42625","article-title":"Identification of covariates modulating B-cell repopulation kinetics in subjects receiving rituximab treatment","volume":"75","author":"Welte","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2025.02.002_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584509","article-title":"Monitoring of the complement system status in patients with B-cell malignancies treated with rituximab","volume":"11","author":"Felberg","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.02.002_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.02.002_bib27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transpl"},{"key":"10.1016\/j.ekir.2025.02.002_bib28","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1073\/pnas.1810470115","article-title":"Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease","volume":"115","author":"H\u00e4usler","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2025.02.002_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: Depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2025.02.002_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib31","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/ard-2024-225587","article-title":"Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis","volume":"83","author":"Thiel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/biomedicines9010083","article-title":"Therapeutic targeting of autoreactive B cells: Why, How, and When?","volume":"9","author":"Stensland","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ekir.2025.02.002_bib33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","article-title":"Interstital lung disease in ANCA vasculitis","volume":"16","author":"Alba","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.02.002_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2215\/CJN.03950412","article-title":"Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab","volume":"8","author":"Bunch","year":"2013","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.ekir.2025.02.002_bib35","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1136\/annrheumdis-2014-206756","article-title":"Gleaning relapse risk from B cell phenotype: Decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis","volume":"74","author":"Bunch","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.02.002_bib36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"The effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in ANCA vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.ekir.2025.02.002_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.ekir.2025.02.002_bib38","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin Rheumatol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T23:18:26Z","timestamp":1752794306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2468024925000786"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.02.002","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.03.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}